Ross Products Division to Launch First Soy Infant Formula (Isomil(R)) Containing Martek's Oils

COLUMBIA, Md., Oct. 29 -- Martek Biosciences
Corporation (Nasdaq: MATK) announced today that Abbott Laboratories' Ross
Products Division will launch the first and only soy-based infant formula in
the U.S. to be supplemented with docosahexaenoic acid (DHA) and arachidonic
acid (ARA). The United States Food and Drug Administration (FDA) has
completed its review of Ross' Isomil(R) Advance(R) which will contain a blend
of Martek's DHA and ARA. The formula is expected to be available in stores in
December 2002.
Martek's oils contain the long-chain polyunsaturated fatty acids
(LCPUFAs), DHA and ARA, both of which are found in mother's breast-milk.
Clinical studies have demonstrated numerous benefits for those infants
receiving DHA and ARA-supplemented formula. Martek's proprietary blend of DHA
and ARA is the only source of these nutrients that the FDA has cleared for use
in infant formula.
"Soy-based infant formula offers an important alternative to many infants
with special dietary needs," said Henry Linsert, Jr., Chairman and CEO of
Martek Biosciences Corporation. "A significant number of U.S. infants require
soy formula annually and now these babies will also benefit from DHA and ARA."

Martek Biosciences Corporation develops, manufactures and sells products
from microalgae. The Company's products include: (1) specialty, nutritional
oils for infant formula that aid in the development of the eyes and central
nervous system in newborns; (2) nutritional supplements and food ingredients
that may play a beneficial role in promoting mental and cardiovascular health
throughout life; and (3) new, powerful fluorescent markers for diagnostics,
rapid miniaturized screening, and gene and protein detection.

This press release contains forward-looking statements regarding the
commercialization of Martek's products. Such statements involve risks and
uncertainties that could cause future actual results to differ due to a
variety of risk factors, including without limitation those factors set forth
in Martek's filings with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.